A large portion of biologics fail during development due to issues with efficacy, safety, or manufacturability. Evaluating potential liabilities as early as possible during the molecule design and lead selection phases can greatly increase the chances of identifying a successful candidate. Initial strategies to optimize the amino acid sequence of the molecule will be discussed along with techniques to maximize product quality through expression vector design.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center